Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APSMNF in Male Androgenetic Alopecia
NCT07516561Phase 3Not yet recruiting
- Sponsor
- Apsen Farmacêutica
- Start
- Oct 2026
- Primary completion
- Aug 2029
- Countries
- 1
01
Overview
A Phase 3 trial of APSMNF 1 in androgenetic alopecia (AGA), sponsored by Apsen Farmacêutica. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
APSMNF 1
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on NCT07516561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07516561.